CN1112215C - 神经生长因子在治疗有机溶剂中毒性周围神经病中的用途 - Google Patents
神经生长因子在治疗有机溶剂中毒性周围神经病中的用途 Download PDFInfo
- Publication number
- CN1112215C CN1112215C CN99127304A CN99127304A CN1112215C CN 1112215 C CN1112215 C CN 1112215C CN 99127304 A CN99127304 A CN 99127304A CN 99127304 A CN99127304 A CN 99127304A CN 1112215 C CN1112215 C CN 1112215C
- Authority
- CN
- China
- Prior art keywords
- group
- ngf
- nerve
- rat
- control group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108010025020 Nerve Growth Factor Proteins 0.000 title claims abstract description 151
- 208000033808 peripheral neuropathy Diseases 0.000 title claims abstract description 49
- 239000003960 organic solvent Substances 0.000 title claims abstract description 15
- 102000015336 Nerve Growth Factor Human genes 0.000 title claims description 149
- 229940053128 nerve growth factor Drugs 0.000 title claims description 149
- 231100000331 toxic Toxicity 0.000 title abstract description 26
- 230000002588 toxic effect Effects 0.000 title abstract description 26
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims abstract description 26
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims description 21
- 206010008428 Chemical poisoning Diseases 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 3
- 102000007072 Nerve Growth Factors Human genes 0.000 abstract 2
- 241000700159 Rattus Species 0.000 description 120
- 210000003414 extremity Anatomy 0.000 description 73
- 230000036982 action potential Effects 0.000 description 60
- 230000033001 locomotion Effects 0.000 description 58
- 210000003141 lower extremity Anatomy 0.000 description 33
- 238000000034 method Methods 0.000 description 31
- 210000005012 myelin Anatomy 0.000 description 31
- 108010083674 Myelin Proteins Proteins 0.000 description 30
- 102000006386 Myelin Proteins Human genes 0.000 description 30
- 238000011534 incubation Methods 0.000 description 30
- 210000005036 nerve Anatomy 0.000 description 29
- 239000000835 fiber Substances 0.000 description 26
- MWVFCEVNXHTDNF-UHFFFAOYSA-N hexane-2,3-dione Chemical group CCCC(=O)C(C)=O MWVFCEVNXHTDNF-UHFFFAOYSA-N 0.000 description 23
- 230000007850 degeneration Effects 0.000 description 21
- 230000003387 muscular Effects 0.000 description 19
- 210000002972 tibial nerve Anatomy 0.000 description 19
- 238000000465 moulding Methods 0.000 description 18
- 230000001537 neural effect Effects 0.000 description 16
- 206010042674 Swelling Diseases 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- 230000008961 swelling Effects 0.000 description 15
- 238000011109 contamination Methods 0.000 description 13
- 210000003050 axon Anatomy 0.000 description 12
- 210000003497 sciatic nerve Anatomy 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 231100000614 poison Toxicity 0.000 description 10
- 238000010255 intramuscular injection Methods 0.000 description 9
- 239000007927 intramuscular injection Substances 0.000 description 9
- 210000000629 knee joint Anatomy 0.000 description 9
- 231100000572 poisoning Toxicity 0.000 description 9
- 230000000607 poisoning effect Effects 0.000 description 9
- 210000004126 nerve fiber Anatomy 0.000 description 8
- 239000000463 material Substances 0.000 description 7
- 230000001575 pathological effect Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 241000053227 Themus Species 0.000 description 6
- 210000000544 articulatio talocruralis Anatomy 0.000 description 6
- 230000004888 barrier function Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000005611 electricity Effects 0.000 description 6
- 238000007689 inspection Methods 0.000 description 6
- 230000007830 nerve conduction Effects 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 206010028372 Muscular weakness Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- 230000036473 myasthenia Effects 0.000 description 5
- 210000000578 peripheral nerve Anatomy 0.000 description 5
- 239000002574 poison Substances 0.000 description 5
- 230000007096 poisonous effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 208000012661 Dyskinesia Diseases 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 206010067722 Toxic neuropathy Diseases 0.000 description 4
- 231100000126 Toxic neuropathy Toxicity 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000007831 electrophysiology Effects 0.000 description 4
- 238000002001 electrophysiology Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 210000000653 nervous system Anatomy 0.000 description 4
- 201000001119 neuropathy Diseases 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 102000002151 Microfilament Proteins Human genes 0.000 description 3
- 108010040897 Microfilament Proteins Proteins 0.000 description 3
- 230000003376 axonal effect Effects 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000000916 dilatatory effect Effects 0.000 description 3
- 210000003632 microfilament Anatomy 0.000 description 3
- 230000007659 motor function Effects 0.000 description 3
- 230000007823 neuropathy Effects 0.000 description 3
- 208000027232 peripheral nervous system disease Diseases 0.000 description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010017577 Gait disturbance Diseases 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 206010029350 Neurotoxicity Diseases 0.000 description 2
- 208000037169 Retrograde Degeneration Diseases 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 230000005021 gait Effects 0.000 description 2
- 210000004394 hip joint Anatomy 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000035987 intoxication Effects 0.000 description 2
- 231100000566 intoxication Toxicity 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 238000011712 neuropathy animal model Methods 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012207 quantitative assay Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000004116 schwann cell Anatomy 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 241000252229 Carassius auratus Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000010886 Peripheral nerve injury Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010040026 Sensory disturbance Diseases 0.000 description 1
- 206010073696 Wallerian degeneration Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000009193 crawling Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- YHVACWACSOJLSJ-UHFFFAOYSA-N n-methyl-n-(1-oxo-1-phenylpropan-2-yl)nitrous amide Chemical compound O=NN(C)C(C)C(=O)C1=CC=CC=C1 YHVACWACSOJLSJ-UHFFFAOYSA-N 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000004417 patella Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000001243 pseudopodia Anatomy 0.000 description 1
- 210000002097 psoas muscle Anatomy 0.000 description 1
- ALZOLUNSQWINIR-UHFFFAOYSA-N quinmerac Chemical compound OC(=O)C1=C(Cl)C=CC2=CC(C)=CN=C21 ALZOLUNSQWINIR-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000003516 soil conditioner Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000001913 submandibular gland Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 230000008734 wallerian degeneration Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN99127304A CN1112215C (zh) | 1999-12-28 | 1999-12-28 | 神经生长因子在治疗有机溶剂中毒性周围神经病中的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN99127304A CN1112215C (zh) | 1999-12-28 | 1999-12-28 | 神经生长因子在治疗有机溶剂中毒性周围神经病中的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1301570A CN1301570A (zh) | 2001-07-04 |
CN1112215C true CN1112215C (zh) | 2003-06-25 |
Family
ID=5284855
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN99127304A Ceased CN1112215C (zh) | 1999-12-28 | 1999-12-28 | 神经生长因子在治疗有机溶剂中毒性周围神经病中的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1112215C (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4342485A1 (en) * | 2022-09-23 | 2024-03-27 | Dompe' Farmaceutici S.P.A. | Ngf for the treatment of spasticity |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104161771A (zh) * | 2014-04-09 | 2014-11-26 | 大连医科大学 | 骨髓间充质干细胞来源的神经细胞作为治疗正己烷致周围性神经病的药物的应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1052141A (zh) * | 1989-08-30 | 1991-06-12 | 马克斯普朗克精神病学院 | 神经营养因子-3-一种与神经生长因子和脑衍生的神经营养因子有关的新的神经营养因子 |
DE4125933A1 (de) * | 1991-08-05 | 1993-02-11 | Max Planck Gesellschaft | Verbesserung der regeneration von oligodendrocyten |
CN1071585A (zh) * | 1991-07-10 | 1993-05-05 | 里珍纳龙药品有限公司 | 应用bdnf/nt-3/ngf分子族成员治疗运动神经元疾病的方法 |
WO1998046254A1 (en) * | 1997-04-11 | 1998-10-22 | Roche Diagnostics Gmbh | Ngf for the prevention of demyelination in the nervous system |
-
1999
- 1999-12-28 CN CN99127304A patent/CN1112215C/zh not_active Ceased
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1052141A (zh) * | 1989-08-30 | 1991-06-12 | 马克斯普朗克精神病学院 | 神经营养因子-3-一种与神经生长因子和脑衍生的神经营养因子有关的新的神经营养因子 |
CN1071585A (zh) * | 1991-07-10 | 1993-05-05 | 里珍纳龙药品有限公司 | 应用bdnf/nt-3/ngf分子族成员治疗运动神经元疾病的方法 |
DE4125933A1 (de) * | 1991-08-05 | 1993-02-11 | Max Planck Gesellschaft | Verbesserung der regeneration von oligodendrocyten |
WO1998046254A1 (en) * | 1997-04-11 | 1998-10-22 | Roche Diagnostics Gmbh | Ngf for the prevention of demyelination in the nervous system |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4342485A1 (en) * | 2022-09-23 | 2024-03-27 | Dompe' Farmaceutici S.P.A. | Ngf for the treatment of spasticity |
WO2024062135A1 (en) * | 2022-09-23 | 2024-03-28 | Dompe' Farmaceutici Spa | Ngf for the treatment of spasticity |
Also Published As
Publication number | Publication date |
---|---|
CN1301570A (zh) | 2001-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1178912C (zh) | 旋转异构酶活性的小分子抑制剂 | |
CN1356104A (zh) | 全身给药的镇痛方法 | |
CN1774257A (zh) | 制备富含羟基积雪草苷和特米诺苷的积雪草酸提取物的方法 | |
CN1301543A (zh) | 皮肤外用剂 | |
CN1112215C (zh) | 神经生长因子在治疗有机溶剂中毒性周围神经病中的用途 | |
CN1172952C (zh) | 甘露聚糖肽组合物及其制备工艺和用途 | |
CN1711099A (zh) | 具有抗肿瘤和抗毒活性的提取物 | |
CN1593583A (zh) | 治疗骨折的复方制剂及其制备方法 | |
CN1957999A (zh) | 一种中药组合物及其制备方法和质量控制方法 | |
CN1895263A (zh) | 牛磺酸在制备含有葛根素的注射剂中的应用 | |
CN1552439A (zh) | 心肌肽素及其用途 | |
CN1557352A (zh) | 菊苣水提取物的新用途 | |
CN1112439A (zh) | 治疗糖尿病的中药及其生产方法 | |
CN1175877C (zh) | 一枝黄花注射用脂肪乳剂及制备方法 | |
CN1586604A (zh) | 一种莪术注射制剂及其制备方法 | |
CN1565573A (zh) | 一种具有提高智力、改善脑能量代谢、促进脑发育和增强多巴胺能神经功能作用的组合物及其制备工艺和用途 | |
CN1256081C (zh) | 鸦胆子油乳注射液的制备方法 | |
CN1726934A (zh) | 血府逐瘀药物组合物在制备降血脂药物中的应用 | |
CN1101565A (zh) | 一种防治人流术后并发症的药物及其制造方法 | |
CN1100062C (zh) | 一种治疗早老性痴呆和及脑卒中后遗症的新药 | |
CN1548156A (zh) | 一种治疗性乙型肝炎的疫苗制剂、其制备方法及其用途 | |
CN1565530A (zh) | 一种治疗尿失禁的药物及其制备方法 | |
CN100341520C (zh) | 一种具有抗疲劳和延缓衰老功能的鲨烯复合剂 | |
CN1287835C (zh) | 一种治疗冠心病、心绞痛的药物组合物及其制备方法 | |
CN1168739C (zh) | 水仙子糖肽及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: XIA GUIYING Free format text: FORMER OWNER: PAN XIAODONG Effective date: 20070105 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20070105 Address after: 067000 Chengde City, Hebei province Shuangqiao District Peach Street West 6 - 3 - 522 Patentee after: Xia Guiying Address before: 100039, Beijing, Haidian District Fuxing Road, No. 38 Guardian apartment 523 Patentee before: Pan Xiaodong |
|
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Xia Guiying Document name: Notice of conformity |
|
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Xia Guiying Document name: Notification of Acceptance of Request for Invalidation |
|
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Xiamen Bioway Biotech Co., Ltd. Assignor: Xia Guiying Contract fulfillment period: 2008.12.24 to 2019.12.28 Contract record no.: 2008351000080 Denomination of invention: Use of nerve growth factor in curing organic solvent toxic peripheral neuropathy Granted publication date: 20030625 License type: General permission Record date: 20081230 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: COMMON LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2008.12.24 TO 2019.12.28; CHANGE OF CONTRACT Name of requester: XIAMEN BEIDAZHILU BIOLOGICAL ENGINEERING CO., LTD. Effective date: 20081230 |
|
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Xia Guiying Document name: Notification of Acceptance of Request for Invalidation |
|
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Xia Guiying Document name: Notification of Oral Hearing for Request for Invalidation |
|
C35 | Partial or whole invalidation of patent or utility model | ||
IW01 | Full invalidation of patent right |
Decision date of declaring invalidation: 20100414 Decision number of declaring invalidation: 14662 Granted publication date: 20030625 |
|
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: 067000 room four, unit 2908, Fuhua new world, Chengde, Hebei Patentee after: Xia Guiying Address before: 100071 Beijing city Fengtai District Feng Bao Road No. 168 F6B Patentee before: Xia Guiying |